Lixisenatide added to basal insulin reduces glycaemic variability in patients with type 2 diabetes mellitus
Background and aims: This analysis evaluated the impact on glycaemic variability (GV) of lixisenatide (LIXI) vs placebo (PBO) as add-on to basal insulin ± oral antidiabetes drugs (OADs) in patients with type 2 diabetes mellitus (T2DM). Materials and methods: Patient-level data from GetGoal-L, GetGoa...
Autores Principales: | , , , , , , , , |
---|---|
Formato: | Objeto de conferencia (Conference Object) |
Lenguaje: | Inglés (English) |
Publicado: |
Springer Nature
2014
|
Materias: | |
Acceso en línea: | https://repository.urosario.edu.co/handle/10336/25608 https://doi.org/10.1007/s00125-014-3355-0 |